Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of biphenyl derivatives and is structurally a conformationally constrained D-Tic derivative. It has been studied as an experimental inhibitor of matrix metalloproteinase 8 (MMP8; also known as human neutrophil collagenase). The molecule binds to the S(1)' subsite of MMP8 and induces structural changes in the enzyme's active site. Its mechanism involves non-hydroxamate zinc-binding functions that interact with the catalytic zinc ion in MMP8. The compound has not been approved for any clinical use and remains at an experimental stage[1][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(Biphenyl-4-Sulfonyl)-1,2,3,4-Tetrahydro-Isoquinoline-3-Carboxylic Acid.